Accumulus Technologies launched Direct Connect for Veeva RIM, enabling real-time integration between regulatory information management systems and health authorities. The integration allows life sciences companies to manage regulatory interactions seamlessly within Veeva RIM while using Accumulus as a central global interface to regulators, reducing manual work and streamlining submission processes.

Accumulus Technologies has launched Accumulus Direct Connect for Veeva RIM, enabling real-time integration between regulatory information management systems and health authorities. The integration allows life sciences companies to streamline regulatory submissions and interactions within their existing Veeva RIM environment while using Accumulus as a single global connection point with regulators. Early adopter Amgen reports significant operational improvements including time savings and enhanced visibility.

The article recommends two growth stocks for long-term investors: Nvidia and Veeva Systems. Nvidia continues to lead the AI chip market with strong financial results and upcoming product releases expected to drive $1 trillion in orders through 2027. Veeva Systems, despite competitive pressures, maintains dominance in life sciences cloud solutions with high switching costs and strong financial growth, positioning both stocks as attractive investments for patient investors with a 5+ year horizon.

U.S. equities reached all-time highs on Friday as Apple's blowout Q2 earnings powered a broad technology rally. The S&P 500 advanced 0.7% to 7,262, while the Nasdaq 100 rose 1.1% to 27,743. Apple surged 5.1% on strong revenue and guidance, while software stocks like Atlassian, Twilio, and Reddit soared on earnings beats. Energy stocks declined as crude oil fell over 3%. Some mega-cap earnings disappointed, including Amgen and Roblox, which posted significant declines.

The clinical trial management system (CTMS) market is experiencing significant growth, expanding from $2.25 billion in 2025 to $2.54 billion in 2026 at a 13.1% CAGR, with projections reaching $4.2 billion by 2030. Growth is driven by increasing global clinical trials, adoption of cloud-based platforms, AI-powered analytics, and decentralized trial models. Key players are making strategic moves including platform launches and acquisitions to enhance technological capabilities.

The AI clinical trial protocol feasibility tool market is experiencing rapid expansion, growing from $0.83 billion in 2025 to $1.06 billion in 2026 with a 27.3% CAGR. The market is projected to reach $2.76 billion by 2030, driven by increasing protocol complexity, precision medicine focus, decentralized trial designs, and AI-enabled protocol optimization. Key players include IQVIA Holdings, SAS Institute, Veeva Systems, and Tempus AI, with North America leading and Asia-Pacific emerging as the fastest-growing region.

The clinical trial software market is expected to grow from $1.32 billion in 2025 to $2.53 billion by 2030, with a CAGR of 13.8%. Growth drivers include increased digitization, adoption of AI and cloud-based solutions, virtual and decentralized trials, and enhanced data security focus. Major players are innovating with unified trial solutions and strategic acquisitions to strengthen their market positions.

Veeva Systems, a cloud software leader for life sciences companies, has declined 37% over six months due to competition concerns. However, the article argues the stock is now attractive due to its strong market position, AI investments, large addressable market ($20B+), and valuation at forward P/E of ~20, suggesting potential for strong returns over the next five years.

Veeva Systems has delivered solid 13.6% CAGR returns since its 2013 IPO and could help investors build multimillion-dollar portfolios over 30 years. The cloud specialist serves the life sciences industry with strong competitive advantages, including high switching costs and leadership among top biopharma companies. Despite facing increased competition and slowing revenue growth, Veeva's large addressable market ($20B) and expansion into new sectors position it well for long-term growth.

U.S. stock futures declined on Thursday following geopolitical tensions in the Middle East, with reports of Iran initiating contact with Trump for ceasefire negotiations. The S&P 500 and Nasdaq 100 fell slightly in premarket trading. Notable movers included Broadcom surging 6.66% on better-than-expected Q1 results, Veeva Systems rising 11.32% on strong guidance, Trade Desk jumping 16.85% following insider buying, and Webull falling 3.13% after missing profit targets.

The article recommends two growth stocks for long-term investors: Eli Lilly, a pharmaceutical leader in anti-obesity medicines with strong double-digit growth and AI-powered drug development initiatives, and Veeva Systems, a cloud solutions provider for life science companies with a $20 billion addressable market and a goal to double revenue by 2030.

The global pharmacovigilance market is projected to grow from USD 8.91 billion in 2025 to USD 24.69 billion by 2035, at a CAGR of 10.34%. Growth is driven by stringent regulatory requirements, increased adverse drug reaction incidents, and pharmaceutical industry expansion into emerging markets. The U.S. market alone is expected to reach USD 9.48 billion by 2035. Phase IV post-market surveillance and contract outsourcing services dominate the market segments.